<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841070</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/21/0186</org_study_id>
    <nct_id>NCT04841070</nct_id>
  </id_info>
  <brief_title>NEURodevelopmental Outcome After Persistent Pulmonary Hypertension Of the Newborn</brief_title>
  <acronym>NEUROPHON</acronym>
  <official_title>NEURodevelopmental Outcome in Children Between One and Five Years After Persistent Pulmonary Hypertension Of the Newborn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neonatal pulmonary hypertension is a rare but serious condition resulting from a lack of&#xD;
      adaptation to extra-uterine life in some newborns. In the short term, the risk of death&#xD;
      requires rapid and appropriate management of this transient pathology.&#xD;
&#xD;
      In the long term, these newborns present a greater brain vulnerability, a consequence of the&#xD;
      pathology itself with cerebral hypoxia but also invasive and aggressive therapies. Although&#xD;
      current scientific evidence indicates a correlation with the existence of neurological&#xD;
      developmental disorders, the understanding of the long-term neurological outcome of these&#xD;
      babies remains poorly documented. Better knowledge of remote neuro-psychomotor development of&#xD;
      the critical period&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Describe the association between the occurrence of neuro-psychomotor developmental disorders and initial management in resuscitation.</measure>
    <time_frame>Between one and 5 years after hospitalization in resuscitation.</time_frame>
    <description>Parents will complete ASQ3. The investigators will consider neuro-psychomotor developmental disorders in children with pathological ASQ questionnaire on at least 2 items.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Persistent Pulmonary Hypertension of the Newborn</condition>
  <arm_group>
    <arm_group_label>Persistent pulmonary hypertension of the newborn.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children aged 1 to 5 years who have been hospitalized in pediatric resuscitation service for the treatment of persistent pulmonary hypertension of the newborn.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ages &amp; Stages QuestionnairesÂ®, Third Edition (ASQ3)</intervention_name>
    <description>Investigators will propose to parents of children hospitalized for the treatment of persistent pulmonary hypertension of the newborn a hetero-evaluation via the validated ASQ questionnaire to analyze neuro-psychomotor development.</description>
    <arm_group_label>Persistent pulmonary hypertension of the newborn.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All parenting authority holders of children aged 1 to 5 years, born after 34 weeks of&#xD;
             amenorrhea and having been cared for neonatal PAH in paediatric resuscitation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Holders of parental authority who cannot answer the questionnaire because they do not&#xD;
             speak French.&#xD;
&#xD;
          -  Opposition of one of the two holders of parental authority&#xD;
&#xD;
          -  Minor parental authority holders&#xD;
&#xD;
          -  Holders of parental authority under safeguarding of justice, guardianship or&#xD;
             guardianship&#xD;
&#xD;
          -  Newborns with neonatal PAH with an associated diagnosis of diaphragmatic hernia or&#xD;
             cyanogenic congenital heart disease&#xD;
&#xD;
          -  Newborns with neonatal PAH not treated with nitrogen monoxide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie BREINIG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie BREINIG, MD</last_name>
    <phone>0534558477</phone>
    <email>breinig.s@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sophie BREINIG, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

